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Co-regulation of genes has been extensively analyzed, however, rather limited knowledge is available on co-regulations within the
miRNome. We investigated diﬀerential co-expression of microRNAs (miRNAs) based on miRNome proﬁles of whole blood from
540 individuals. These include patients suﬀering from diﬀerent cancer and non-cancer diseases, and unaﬀected controls. Using hierarchi-
cal clustering, we found 9 signiﬁcant clusters of co-expressed miRNAs containing 2–36 individual miRNAs. Through analyzing multiple
sequencing alignments in the clusters, we found that co-expression of miRNAs is associated with both sequence similarity and genomic
co-localization. We calculated correlations for all 371,953 pairs of miRNAs for all 540 individuals and identiﬁed 184 pairs of miRNAs
with high correlation values. Out of these 184 pairs of miRNAs, 16 pairs (8.7%) were diﬀerentially co-expressed in unaﬀected controls,
cancer patients and patients with non-cancer diseases. By computing correlated and anti-correlated miRNA pairs, we constructed a net-
work with 184 putative co-regulations as edges and 100 miRNAs as nodes. Thereby, we detected speciﬁc clusters of miRNAs with high
and low correlation values. Our approach represents the most comprehensive co-regulation analysis based on whole miRNome-wide
expression proﬁling. Our ﬁndings further decrypt the interactions of miRNAs in normal and human pathological processes.
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Microarray experiments have been applied for almost three
decades in the detection of disease-relevant changes in gene
expression patterns. While in early ages genes have mostly
been considered independently from each other, cluster
[1,2] and classiﬁcation [3–5] technologies have more
recently been applied to ﬁnd patterns of diﬀerentially
expressed genes. Finally, gene set analysis approaches
[6,7] and methods integrating pathway topology [8,9] have
been developed to understand the interplay of genes. These1672-0229/$ - see front matter  2012 Beijing Institute of Genomics, Chinese A
Ltd and Science Press. All rights reserved.
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E-mail: ack@bioinf.uni-sb.de (Keller A).approaches have been successfully applied to studies in
small non-coding RNAs, e.g., microRNAs (miRNAs).
With the increasing availability of expression proﬁles for
various diseases, diﬀerential co-expression of genes moved
into the focus of attention. The term “diﬀerential co-
expression” was ﬁrstly coined by Bennets in 1986 [10]
studying the co-expression of alpha-actins within the
human heart. In 1992, Swiderski reported diﬀerential co-
expression of long and short form type IX collagen tran-
scripts during avian limb chondrogenesis [11]. Co-expres-
sion analysis of genes using microarray technology has
also been applied to other human pathologies, including
cancer [12]. In 2009, Mo and co-workers presented a
stochastic model to identify co-expression patterns of
diﬀerential gene pairs in prostate cancer progression [13].
Comprehensive methods to detect diﬀerential co-cademy of Sciences and Genetics Society of China. Published by Elsevier
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eﬃcient pattern recognition algorithm [14]. This algorithm
used Expected Conditional F-statistic that incorporates
statistical information of location and correlation or other
scores as proposed by Koska and Spang [15]. Subse-
quently, several tools and software packages with respec-
tive functionality have been developed including
CoXpress [16], DiﬀCoEx [17], dCoxS [18] and diﬀerential
co-expression framework [19].
Only a few studies have been reported for analysis of dif-
ferential co-expression for miRNAs. An example is the
construction of an miRNA–miRNA synergistic network
via co-regulating functional modules and disease miRNA
topological features [20]. One reason for the lack of
miRNA co-expression studies is certainly the paucity of
miRNA expression proﬁling data. Gene expression proﬁles
have been measured for almost three decades in numerous
microarray experiments, of which hundreds of thousands
are currently available through the Gene Expression Omni-
bus [21,22], however, only a fraction of array data sets are
available for miRNAs. The most frequently applied micro-
array platform is the Agilent miRNA microarray 2.0.
Another technology which is frequently applied is the
MPEA assay (Febit Biomed, Heidelberg) that has been
used to measure several hundred blood-based miRNA
proﬁles which are the source for our meta-analysis.
Previously, Riveros and co-workers reported a compre-
hensive study for diﬀerential co-expression of miRNA that
was derived from whole blood of patients with multiple
sclerosis [23], providing evidence that diﬀerential co-expres-
sion from body ﬂuids can be accessed. miRNA expressionFigure 1 Cluster dendrogram of miRNAs
Red boxes denote signiﬁcant clusters as computed by bootstrap re-sampling. T
corresponding to signiﬁcance level of 0.05, are considered as signiﬁcant. Values
in the dendrogram, respectively. The signiﬁcant clusters with approximately un
circle in increasing order from left to right.patterns from human blood cells are increasingly discussed
for their potential as a minimal invasive diagnostic tool.
Most recently, we reported blood-based miRNA expres-
sion patterns for 14 diﬀerent human pathologies [24]
including lung cancer [25], COPD [26], multiple sclerosis
[27], ovarian cancer [28], glioblastoma [29], and acute
myocardial infarction [30]. Since the various cohorts are
relatively small as compared to the large number of poten-
tial pair-wise co-expressions, we combined the diﬀerent
data sets into a meta-analysis. Here, we investigate the dif-
ferential co-expression patterns using the data of a total of
540 blood-based miRNA expression proﬁles.
Results and discussion
Co-localization and co-expression of miRNAs
As a ﬁrst approach towards understanding the interplay of
miRNAs, we applied hierarchical clustering to the data set
containing 540 samples measured for the expression of 863
miRNAs. To reduce the noise, we excluded miRNAs with
low expression values (detailed in Material and methods).
An average linkage bottom up clustering detected a total
of nine signiﬁcant clusters (P < 0.05). These clusters each
contain 2–36 miRNAs (Figure 1). Notably, many clusters
contained miRNAs with similar sequences. Good example
for co-expression related to similar sequences is Cluster 8
that contains hsa-miR-23a and hsa-miR-23b or Cluster 5
that contains hsa-miR-19a and hsa-miR-19b. The biologi-
cal mechanism underlying co-expression of miRNAs with
similar sequence remains to be elucidated. It is possible thathe red values were calculated by bootstrap re-sampling and those >95%,
in green and gray indicate bootstrap probability (BP) and the edge number
biased (AU) value greater than 95% (P < 0.05) are labeled with numbers in
Figure 2 Alignments of co-expression miRNA clusters with similar or
diﬀerent sequences
Pairwise sequence alignment indicated that hsa-miR-23a and hsa-miR-23b
in Cluster 8 (upper panel) and hsa-miR-19a and hsa-miR-19b in Cluster 5
(middle panel) show high sequence similarity, while there is lower sequence
similarity for hsa-miR-1260 and hsa-miR-30c in Cluster 3 (lower panel).
Table 1 Co-localization of correlated miRNAs
miRNA Position Strand Correlation
Figure 3 Representative expression proﬁles of correlated miRNA pairs
A. Positive correlation. Expression of two positively-correlated miRNAs, hs
controls (n = 72, black circle), cancer patients (n = 276, red circle) and non-ca
two negatively-correlated miRNAs, hsa-miR-423-5p and hsa-miR-144, was me
(red circle) and non-cancer patients (blue circle). A complete list of the diseas
Sta¨ehler CF et al / Diﬀerential miRNA Co-expression 287co-expressed miRNAs of similar sequence share similar
targets. Other than that, reduced speciﬁcity of hybridiza-
tion-based approaches could partially explain this
co-expression. On the other hand, as expected, we also
found many miRNAs that clustered together but had dif-
ferent sequences, such as hsa-miR-1260 and hsa-miR-30c
in Cluster 3. Respective pair-wise sequence alignments
(hsa-miR-19a/hsa-miR-19b, hsa-miR23a/hsa-miR23b,
hsa-miR-1260/hsa-miR-30c) are shown in Figure 2.
To test the hypothesis that miRNAs belonging to the
same polycistronic miRNA cluster or the same miRNA
family are co-expressed, we additionally performed enrich-
ment analyses. For each signiﬁcant set containing more
than 5 miRNAs (Clusters 4, 6 and 7 in Figure 1), we per-
formed the enrichment analysis separately to see whether
the selected miRNA clusters or families are over-
represented. In line with our expectations, the let-7a,
miR-106a, miR-106b, miR-15a and miR-17 clusters were
signiﬁcantly enriched (all P 6 0.005) in our Cluster 6,
whereas members of the miR-192 polycistronic miRNA
cluster were mostly found in Cluster 7 (P = 0.001). Like-
wise, we also found a strong enrichment of miRNA fami-
lies in our clusters, such as the let-7 family (P = 0.002),
the miR-15 family (P = 0.001), the miR-320 family
(P = 0.00002) and the miR-17 family (P = 3E-8) in Cluster
6 and the miR-103 family (P = 0.001) in Cluster 7. Interest-
ingly, no signiﬁcant enrichment for a known miRNA clus-
ter or family was found in Cluster 4, indicating that our
clustering approach groups not only polycistronic (and
thus co-transcribed) miRNA clusters or known miRNA
families, but also miRNAs that are co-expressed for diﬀer-
ent reasons. In addition, divergent behavior of individuala-miR-17 and hsa-miR-20a, was measured for 540 individuals including
ncer patients (n = 192, blue circle). B. Negative correlation. Expression of
asured for 540 individuals including controls (black circle), cancer patients
e types and the respective numbers of patients is shown in Table 4.
Table 2 Diﬀerential co-expression in diseases
miRNA 1 miRNA 2 Overall correlation Control correlation Cancer correlation Non cancer correlation Variance
hsa-miR-377* hsa-miR-548l 0.756 0.129 0.522 0.842 0.245
hsa-miR-196b hsa-miR-548l 0.73 0.028 0.416 0.864 0.199
hsa-miR-548l hsa-miR-135b 0.72 0.023 0.373 0.863 0.197
hsa-miR-423-5p hsa-miR-144 0.556 0.052 0.651 0.462 0.132
hsa-miR-595 hsa-miR-574-5p 0.743 0.121 0.78 0.62 0.118
hsa-miR-363 hsa-miR-320d 0.507 0.019 0.481 0.624 0.114
hsa-miR-320c hsa-miR-363 0.519 0.022 0.539 0.56 0.093
hsa-miR-320b hsa-miR-144 0.575 0.078 0.619 0.582 0.091
hsa-miR-106a hsa-miR-720 0.577 0.128 0.626 0.582 0.076
hsa-miR-106a hsa-miR-320c 0.504 0.068 0.499 0.568 0.073
hsa-miR-144 hsa-miR-320a 0.571 0.143 0.642 0.542 0.07
hsa-miR-126 hsa-miR-720 0.513 0.079 0.537 0.534 0.069
hsa-miR-144 hsa-miR-720 0.552 0.144 0.584 0.56 0.061
hsa-miR-720 hsa-miR-20b 0.58 0.187 0.599 0.602 0.057
hsa-miR-23b hsa-miR-23a 0.708 0.323 0.751 0.709 0.056
hsa-miR-17 hsa-miR-151-3p 0.512 0.205 0.378 0.657 0.052
288 Genomics Proteomics Bioinformatics 10 (2012) 285–294miRNAs belonging to the same polycistronic cluster or
family provides evidence for a signiﬁcant post-transcrip-
tional component in miRNA expression.
An additional reason for putative co-regulation of miR-
NAs might be their co-localization in the genome. To this
end, we searched for miRNAs that have been clusteredFigure 4 Correlations of 16 miRNA pairs with variance > 0.05
Diﬀerential co-expression of these miRNA pairs is shown separately for canc
Co-expression of the miRNA pairs was more frequently detected in cancer antogether based on the expression data and are located on
the same chromosome. Subsequently candidate pairs were
mapped to the exact chromosomal position. We found ﬁve
pairs of miRNAs that showed a high absolute correlation
(60.5 orP0.5) and are located on the same chromosome,
as presented in Table 1. Three of those ﬁve miRNA pairser patients (red), non-cancer patients (green) and healthy controls (blue).
d non-cancer patients than in healthy controls.
Table 3 Non-diﬀerential co-expression in diseases
miRNA 1 miRNA 2 Overall correlation Control correlation Cancer correlation Non-cancer correlation Variance
hsa-miR-593* hsa-miR-646 0.791 0.813 0.803 0.77 <0.001
hsa-miR-93 hsa-miR-20b 0.737 0.758 0.751 0.721 <0.001
hsa-miR-593* hsa-miR-214 0.834 0.815 0.824 0.852 <0.001
hsa-miR-330-3p hsa-miR-621 0.858 0.887 0.859 0.851 <0.001
hsa-miR-593* hsa-miR-331-3p 0.503 0.5 0.488 0.523 <0.001
hsa-miR-374b hsa-miR-374a 0.722 0.729 0.734 0.702 <0.001
hsa-miR-621 hsa-miR-593* 0.838 0.852 0.849 0.822 <0.001
hsa-miR-330-3p hsa-miR-214 0.801 0.825 0.793 0.815 <0.001
hsa-miR-452* hsa-miR-593* 0.748 0.754 0.756 0.727 <0.001
hsa-miR-500 hsa-miR-195 0.532 0.509 0.54 0.52 <0.001
hsa-miR-1228* hsa-miR-149* 0.719 0.755 0.731 0.73 <0.001
hsa-miR-107 hsa-miR-331-3p 0.67 0.685 0.658 0.675 <0.001
hsa-miR-330-3p hsa-miR-452* 0.793 0.809 0.793 0.792 <0.001
hsa-miR-509-5p hsa-miR-933 0.842 0.854 0.841 0.848 <0.001
hsa-miR-584 hsa-miR-362-5p 0.713 0.709 0.703 0.715 <0.001
hsa-miR-1184 hsa-let-7i* 0.792 0.786 0.788 0.792 <0.001
Sta¨ehler CF et al / Diﬀerential miRNA Co-expression 289showed positive correlation while the remaining two pairs
showed negative correlation. The three pairs with positive
correlation are located within a distance of 500 base pairs
of each other and were each on the same strand. On the
other hand, larger genomic distances were found for the
two negatively-correlated miRNA pairs. For example,
the distance between hsa-miR-423-5p and hsa-miR-144Figure 5 Correlations of 16 miRNA pairs with variance 6 0.00053
Diﬀerential co-expression of these miRNA pairs is shown separately for cancer
expression of the miRNA pairs was comparable in the three groups.was about 10 million base pairs (Mb). Moreover,
hsa-miR-423-5p was located on the plus strand whereas
hsa-miR-144 was located on the minus strand. Figure 3
shows expression values of one pair of positively-correlated
miRNAs, namely hsa-miR-20a/hsa-miR-17 (Figure 3A)
and one pair of negatively-correlated miRNAs, namely
hsa-miR-423-5p/hsa-miR-144 (Figure 3B) for 540 analyzedpatients (red), non-cancer patients (green) and healthy controls (blue). Co-
Figure 6 Correlation network
Network was constructed with all positive correlations between pairs of miRNAs with a correlation of at least 0.7 (blue edges) and all negative correlations
of at least 0.5 (red edges). The thickness of the edges corresponds to the alignment score. The pair-wise sequence alignment was computed using edit
distance. Dashed edges indicate correlations that were diﬀerent in controls and in patients.
290 Genomics Proteomics Bioinformatics 10 (2012) 285–294blood samples. The results showed that the cohorts
behaved similarly for each of the pairs.
Diﬀerential co-expression of miRNAs
The 540 individuals participating in this study can be
grouped in three diﬀerent cohorts, including unaﬀected
healthy individuals (control), cancer patients (cancer) and
non-cancer patients (non cancer). For these three cohorts
we asked whether the correlation is equally high in all three
groups or whether certain cohorts deviate from the others.
To this end, we computed for each pair of miRNAs the
correlation values for the three cohorts separately. As aresult of the calculation for all
863
2
 
¼ 863  862
2
¼ 371; 953 pairs, the values of correla-
tion range from 0.67 to 0.89 with average correlation of
0.013. As the slight positive average correlation already
indicates, we obtained slightly more positive correlations
than negative ones. Thus, we applied diﬀerent thresholds
for positive and negative correlations to acknowledge this
non-symmetric distribution. We only considered posi-
tively-correlated miRNA pairs with correlation values
higher than 0.7 and negatively-correlated miRNA pairs
with values lower than 0.5. Using these thresholds we
obtained 184 miRNA pairs out of 371,953 pairs in total
Sta¨ehler CF et al / Diﬀerential miRNA Co-expression 291(0.05%). Of these 184 miRNA pairs, 118 were positively
correlated and 66 were negatively correlated. To estimate
the extent of diﬀerential expression in the 3 cohorts, we
computed the variance of the correlation values, ranging
from 105 to 0.24 with an average of 0.02. The 16 miRNA
pairs with the highest variance, corresponding to the most
diﬀerentially-regulated miRNAs (variance >0.05), are sum-
marized in Table 2 and Figure 4 and the 16 miRNA pairs
with the lowest variance (variance 60.00053) are indicated
in Table 3 and Figure 5.
By examining the diﬀerential co-expression of the 16
miRNA pairs with variance >0.05, we found that both
the cancer patients and the non-cancer patients deviate
from the healthy controls. As compared to the healthy con-
trols, co-expression of these 16 miRNA pairs was detected
signiﬁcantly more frequently in both cancer and non-can-
cer disease groups. Overall the correlation between cancer
and non-cancer diseases was 0.95 while decreased correla-
tion was revealed between control and cancer and between
control and non-cancer diseases, which is 0.59 and 0.49,
respectively. Further analysis identiﬁed ﬁve miRNA pairs
that were positively correlated in patients but not in
healthy controls. For example, the pair hsa-miR-23a/hsa-
miR-23b showed correlation of 0.71 in non-cancer patients
(P < 1010) and 0.75 in cancer patients (P < 1010) but only
0.32 in healthy controls (P < 0.01) with the respective 95%
conﬁdence intervals as 0.69–0.80, 0.63–0.79 and 0.07–0.54.
Moreover, we found 11 miRNAs that were highly anti-
correlated, i.e., negatively correlated both in cancer and
in non-cancer patients but again not correlated in healthy
controls.
These results indicate that the observed overall high var-
iance for the 16 miRNA pairs is mostly due to the healthy
controls. While the 16 pairs were only weakly correlated in
healthy controls they were correlated or anti-correlated in
the patients. The results that may be biased due to slightly
diﬀerent cohort sizes may give ﬁrst and certainly only pre-
liminary evidence that miRNA expression may be moreFigure 7 Diﬀerential co-expression sub-network
Sub-network of miRNAs was constructed with correlations that were diﬀerent
between controls and patients (right side). The indication of edges was same ahomogenously coordinated in patients, possibly indicating
a change in expression regulation that is common to diﬀer-
ent types of diseases.
Interestingly, all miRNAs of the miRNA pairs that are
negatively correlated in cancer or non-cancer patients but
not in healthy controls have been previously related to
human diseases according to the Human miRNA and
Disease Database (HMDD) [31]. For examples, the known
disease-associated miRNAs that were identiﬁed as nega-
tively correlated in our study included hsa-miR-17 that
was according to the HMDD associated with 33 diﬀerent
diseases, hsa-miR-128 with 18 diseases, hsa-miR-20b with
9 diseases, hsa-miR-423 with 4 diseases and hsa-miR-363
with 3 diseases. This ﬁnding is even more profound, since
only about one third of all known miRNAs in the HMDD
are related to one or more diseases [31]. Obviously, the
analysis of co-expression can contribute to the identiﬁca-
tion of disease-associated miRNAs.
Anti-correlation of expression and co-localization of
miRNAs
Besides pairs of miRNAs that were correlated in patients
and that were co-localized, we also identiﬁed co-localiza-
tion of miRNA pairs for miRNAs which are anti-
correlated in patients. For example, hsa-miR-423-5p and
hsa-miR-144 are co-localized on chromosome 17 and are
negatively correlated (0.56). Speciﬁcally, the correlation
value for this miRNA pair was0.65 in non-cancer patients
and 0.46 in cancer patients, respectively. However, we did
not ﬁnd a negative correlation for this miRNA pair in
healthy controls (correlation of 0.05) (Tables 1 and 2).
Putative co-regulation network
Based on the analysis of co-regulated miRNAs, we con-
structed a network with 184 correlations (correlation value
>0.7 or <0.5). As shown in Figure 6, the derived networkbetween controls and patients (left side) and correlations that were similar
s that used in Fig. 6.
Table 4 Cohort characteristics
Class Disease No. of samples
Control Healthy 72
Cancer Lung tumor 35
Ductal adenocarcinoma 45
Melanoma 35
Ovarian cancer 15
Prostate carcinoma 35
Wilms tumor 50
Other pancreatic tumors 48
Tumor of stomach 13
Non cancer Multiple sclerosis 23
Sarcoidosis 45
Periodontitis 18
COPD 27
Myocardial infarction 20
Pancreatitis 37
Benign prostate hyperplasia 22
Sum 540
Note: COPD, chronic obstructive pulmonary disease.
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can be divided into one large connected component and
several small components consisting of 2 to 4 miRNAs
each. The large connected component can again be subdi-
vided into two clusters. The upper cluster shown in Figure 6
contains mostly positively correlated miRNA pairs as indi-
cated by blue edges while the cluster shown at the bottom
of Figure 6 contains both positive correlations and negative
correlations (indicated by red edges). While the miRNAs in
the upper cluster do not show obvious sequence similarity
as indicated by thin edges, positively correlated miRNAs of
the lower cluster show high sequence similarity as indicated
by thick edges. The small components with two to four
miRNAs are mostly positively correlated. For most of
these pairs, the positive correlation is associated with
sequence similarities, as for example for the pair of
hsa-miR-23a and hsa-miR-23b and the pair of hsa-miR-
1247a and hsa-miR-1247b.
Additionally, many of the positive and negative correla-
tions shown in the bottom cluster are diﬀerent between
healthy controls and patients. The diﬀerences are visualized
as a sub-network in Figure 7. The sub-network separates
miRNAs with diﬀerent correlation between healthy con-
trols and patients (on the left) and miRNAs with similar
correlations in healthy controls and patients (on the right).
Among the miRNAs with similar correlations are four
miRNAs of the let-7 family that have previously been asso-
ciated with many human malignancies [31]. In addition,
each of the remaining miRNAs of the sub-network has
previously been associated with at least one human disease
according to the HMDD [31].Conclusion
Over almost three decades it has been shown that co-
expression and speciﬁcally diﬀerential co-expression ofgenes play an important role in human pathogenic pro-
cesses. However, diﬀerential co-expression has not been
thoroughly analyzed for the miRNome. This is in part
due to the lack of respective high-throughput data sets
allowing the analysis of miRNA-miRNA interactions.
We enlarged a recently published set of 454 whole miR-
Nome proﬁles [24] to a total of 540 proﬁles. Analysis of
the miRNA co-expression from these proﬁles provides sup-
porting evidence that genomic localization and sequence
similarity are associated with co-expression. In addition,
we report a signiﬁcantly enriched clustering for miRNAs
that belong to the same miRNA families or polycistronic
miRNA clusters. Moreover, our ﬁndings also support that
the co-expression may be more pronounced in patients,
compared to the healthy controls. Network based analysis
allows us to detect speciﬁc clusters of miRNAs with high
and low correlation. Interestingly, many of the identiﬁed
diﬀerentially co-expressed miRNAs have previously been
associated with human pathogenic processes. Notably,
the reported data have not been measured from tissues
but from blood cells. Since diﬀerent tissues have speciﬁc
miRNA proﬁles, a co-expression analysis would make
sense only for one tissue type but not enabling a meta-anal-
ysis of diﬀerent diseases. However, diﬀerent blood cell com-
positions in diﬀerent diseases might inﬂuence the overall
result of our meta-analysis. Another limitation of our study
is certainly the applied microarray technology. Novel
approaches such as next-generation small RNA sequencing
will likely improve the speciﬁcity of respective analyses in
the future.
In summary, in human diseases, co-expression and
diﬀerential co-expression of miRNAs seems to be of similar
importance to co-expression of protein-coding genes.Materials and methods
Patients
The screened cohort contains a total of 540 subjects includ-
ing healthy controls (n = 72), cancer patients (n = 276) and
patients with non-cancer diseases (n = 192). The detailed
characteristics of the cohort are listed in Table 4. All blood
donors participating in this study signed the informed con-
sent form and the local ethics committee approved the
analysis of miRNA expression in blood. Blood samples
were collected using PAXgene Blood RNA tubes (BD,
Franklin Lakes, New Jersey, USA).miRNA extraction and microarray screening
Total RNA isolation was performed using miRNeasy Mini
Kit (Qiagen) as described previously [25].
Microarray analyses were done on the Geniom RT Ana-
lyzer using Geniom miRNA Biochips (Febit Biomed
GmbH). Each of the 863 human miRNAs (Sanger miR-
Base v12.0 to v15.0) was present in at least seven replicates
Sta¨ehler CF et al / Diﬀerential miRNA Co-expression 293on each of the 540 arrays. The screening was done using
micro-ﬂuidics primer extension assay (MPEA) [32]. This
assay diﬀers from a standard hybridization assay in that
it includes an additional primer extension step. The MPEA
assay is veriﬁed to be very sequence-speciﬁc at the end of
miRNAs and thus minimizes the cross-hybridization
eﬀect, which is of especially high importance for our cross-
hybridization study.Data processing and bioinformatics analysis
At the ﬁrst preprocessing step, all arrays were locally back-
ground corrected. Then, the replicates of each miRNA on
each microarray were merged by computing the median
intensity value. To account for between-array eﬀects, stan-
dard quantile normalization was performed [33], which
showed superior performance as compared to normaliza-
tion via spike-in or housekeeping miRNAs in previous
experiments. All computations then were carried out on
the expression matrix containing 863 rows representing
863 miRNAs and 540 columns representing the 540 indi-
viduals. The statistical analyses were carried out using R
[34] if not mentioned otherwise. To reduce the noise, we
excluded miRNAs with low expression values, i.e., the
median signal intensity of a miRNA must be great than
500 for a speciﬁc miRNA to be considered in our study.
For hierarchical clustering, the pvclust package has been
used. The package computes P values for hierarchical clus-
tering based on a multiscale bootstrap resampling, helping
to interpret clusters. Speciﬁcally, clusters that are highly
supported by the data will have low P values while weaker
clusters end up with non-signiﬁcant P values. Signiﬁcant
clusters are enclosed with red boxes in the respective
dendrogram. We used 1-abs(cor(x,y)) as a distance mea-
sure for the clustering, where cor(x,y) corresponds to the
Pearson correlation coeﬃcient of all 540 observations for
two miRNAs x and y. By using this distance function, we
detect miRNAs that are highly correlated and anti-corre-
lated. In more detail, an average linkage bottom up cluster-
ing was carried out.
To compute diﬀerential expression and diﬀerential co-
expression, we again used the pair-wise Pearson correlation
of all 863 miRNAs, for all 540 samples together but also
for the diﬀerent groups of controls, cancers and non-cancer
diseases, separately. As a result of this analysis, we calcu-
lated for
863
2
 
¼ 863  862
2
¼ 371; 953 miRNA pairs
four diﬀerent correlation values, the overall value and the
single values for the three groups. To ﬁnd the miRNA pairs
with diﬀerent behavior in diﬀerent groups, we computed
the variance of the 371,953 pairs as 1
2
ððcorcontrol;i  coriÞ2þ
ðcorcancer;i  coriÞ2ðcornoncancer;i  cor2i ÞÞ, where corcontrol,i
corresponds to the correlation of control samples for a
miRNA pair i, corcancer,i corresponds to the correlation of
cancer samples for a miRNA pair i, cornon-cancer,i corre-
sponds to the correlation of control samples for a miRNApair i, and cori corresponds to the average of the three
correlation values for miRNA pair i.
Empirically, we considered miRNA pairs with correla-
tions above 0.7 as highly co-expressed and with correla-
tions below -0.5 as anti-correlated. Using Cytoscape [35]
we visualized the network of these miRNA pairs and visu-
alized the results using Cytoscapes mapping functionality
with an organic layout.
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